Teva Pharma (TEVA) Tops Q2 EPS by 14c; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Teva Pharma (TEVA) PT Raised to $25 at Credit Suisse
August 3, 2018 9:02 AM EDTCredit Suisse raised its price target on Teva Pharma (NYSE: TEVA) to $25.00 (from $23.00) while maintaining a Outperform rating.
... MoreTeva Pharma (TEVA) PT Raised to $23 at Barclays
August 3, 2018 5:14 AM EDTBarclays raised its price target on Teva Pharma (NYSE: TEVA) to $23.00 (from $20.00) while maintaining a Equalweight rating.
... More